Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is anticipated to issue its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($1.11) per share and revenue of $4.2220 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.38. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The business’s revenue was up 49002.7% on a year-over-year basis. During the same quarter last year, the business earned ($1.25) EPS. On average, analysts expect Keros Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $15.22 on Tuesday. The firm has a 50-day moving average price of $15.44 and a 200-day moving average price of $14.59. The firm has a market capitalization of $463.75 million, a PE ratio of 49.10, a price-to-earnings-growth ratio of 1.96 and a beta of 1.12. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $72.37.

Analyst Ratings Changes

KROS has been the subject of a number of research analyst reports. Wells Fargo & Company initiated coverage on shares of Keros Therapeutics in a report on Monday, October 20th. They set an “overweight” rating and a $26.00 price objective for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright decreased their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Hold” and a consensus price target of $30.00.

Insider Activity

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. The disclosure for this sale is available in the SEC filing. Insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

Several large investors have recently made changes to their positions in KROS. AQR Capital Management LLC purchased a new stake in Keros Therapeutics during the first quarter worth $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Keros Therapeutics by 15.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after buying an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after buying an additional 205,022 shares in the last quarter. Creative Planning boosted its holdings in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after buying an additional 6,948 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in Keros Therapeutics by 16.0% during the second quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after buying an additional 7,146 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.